Protein C pathway in sepsis

被引:56
作者
Esmon, CT
机构
[1] Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA
[3] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA
[4] Howard Hughes Med Inst, Oklahoma City, OK 73104 USA
关键词
anticoagulant; complement; endothelium; endotoxin; EPCR; protein C; sepsis; thrombin; thrombomodulin; thrombosis;
D O I
10.1080/078538902321117823
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The goals of this chapter are to provide a brief review of the biology of the protein C pathway and some of the features of the pathway that make it uniquely positioned to control microvascular coagulation and control the acute inflammatory response. Activated protein C works as an antithrombotic agent by inactivating factors Va and Villa. It Is particularly effective at preventing microvascular thrombosis. Platelets may provide a margin of safety for activated protein C as an antithrombotic. Approximately 25% of the factor VNa in plasma is contained within the platelet and hence resistant to time dependent inactivation by activated protein C. In addition, factor Va bound to the platelet surface is relatively resistant to inactivation by activated protein C. Activated protein C also facilitates clot lysis by inhibiting plasminogen activator inhibitor 1. a process that is accelerated markedly by vitronectin. Inflammatory cytokines like tumor necrosis factor alpha (TNFalpha) and interleukin-1beta (IL-1beta) downregulate two key components of the protein C activation complex, thrombomodulin and the endothelial cell protein C receptor resulting in decreased protein C activation. Activated protein C in turn has been shown in several animal models and in vitro to inhibit TNF elaboration in response to endotoxin. This inhibition appears to be due to diminished nuclear factor kappaB (NF kappaB) expression and nuclear translocation. Activated protein C has been shown to reduce the rate of death due to severe sepsis. This reduction may be due to both the anticoagulant effects as demonstrated by a reduction in D-dimer and inflammatory effects as demonstrated by a reduction in interieukin 6.
引用
收藏
页码:598 / 605
页数:8
相关论文
共 53 条
  • [41] Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner
    Shu, F
    Kobayashi, H
    Fukudome, K
    Tsuneyoshi, N
    Kimoto, M
    Terao, T
    [J]. FEBS LETTERS, 2000, 477 (03) : 208 - 212
  • [42] The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex
    StearnsKurosawa, DJ
    Kurosawa, S
    Mollica, JS
    Ferrell, GL
    Esmon, CT
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (19) : 10212 - 10216
  • [43] TAKANO S, 1990, BLOOD, V76, P2024
  • [44] Neuroprotection by recombinant thrombomodulin
    Taoka, Y
    Okajima, K
    Uchiba, M
    Johno, M
    [J]. THROMBOSIS AND HAEMOSTASIS, 2000, 83 (03) : 462 - 468
  • [45] Taoka Y, 1998, J NEUROSCI, V18, P1393
  • [46] C4B-BINDING PROTEIN EXACERBATES THE HOST RESPONSE TO ESCHERICHIA-COLI
    TAYLOR, F
    CHANG, A
    FERRELL, G
    MATHER, T
    CATLETT, R
    BLICK, K
    ESMON, CT
    [J]. BLOOD, 1991, 78 (02) : 357 - 363
  • [47] The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis
    Taylor, FB
    Stearns-Kurosawa, DJ
    Kurosawa, S
    Ferrell, G
    Chang, ACK
    Laszik, Z
    Kosanke, S
    Peer, G
    Esmon, CT
    [J]. BLOOD, 2000, 95 (05) : 1680 - 1686
  • [48] PROTEIN-C PREVENTS THE COAGGULOPATHIC AND LETHAL EFFECTS OF ESCHERICHIA-COLI INFUSION IN THE BABOON
    TAYLOR, FB
    CHANG, A
    ESMON, CT
    DANGELO, A
    VIGANODANGELO, S
    BLICK, KE
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1987, 79 (03) : 918 - 925
  • [49] A MODEL FOR THROMBIN PROTECTION AGAINST ENDOTOXIN
    TAYLOR, FB
    CHANG, A
    HINSHAW, LB
    ESMON, CT
    ARCHER, LT
    BELLER, BK
    [J]. THROMBOSIS RESEARCH, 1984, 36 (02) : 177 - 185
  • [50] TAYLOR FB, 1991, Patent No. 5009889